First AD

Second AD

Clinical Data on the Approved JAK Inhibitors for Treatment of Myelofibrosis

Advances in Myelofibrosis Treatment and Enhancing Patient Quality of Life

CURE Expert Connections® is a video series designed to help patients and their loved ones along their cancer care journey by offering information and expert advice from leaders in oncology care. Expert medical professionals share their knowledge and insights on an array of topics to allow for a better understanding of what to expect following a cancer diagnosis. Expert Connections hopes to bridge the gap between patients and oncology professionals to ensure no question is left unanswered.

CURE Expert Connections®

An expert discusses the four FDA-approved JAK inhibitors for myelofibrosis - ruxolitinib, fedratinib, pacritinib, and momelotinib.

Diagnosing Myelofibrosis

Assessing Risk Level of Patients With Myelofibrosis

Educational Resources for Patients Diagnosed With Myelofibrosis

Key Patient Goals for Myelofibrosis Management

Management of Anemia in Patients With Myelofibrosis

Adverse Events Seen With JAK Inhibitors for Myelofibrosis

Assessing Treatment Response in Patients With Myelofibrosis

Best Approaches to Switching Therapies for a Patient With Myelofibrosis

Dosing JAK Inhibitors in Patients With Myelofibrosis

Key Takeaways for Patients With Myelofibrosis

Clinical Data on the Approved JAK Inhibitors for Treatment of Myelofibrosis

Latest News